Abstract: Cancer care has arrived at a crossroads. While checkpoint inhibitors and CAR-T cells have rewritten the rules for hematologic malignancies, solid tumors continue to defy durable control. T cell receptor-engineered T cell (TCR-T) therapy occupies a unique niche: unlike CAR-T constructs, TCR-T cells recognize intracellular antigens displayed on major histocompatibil-ity complex molecules, effectively illuminating targets that remain invisible to conventional antibody-based approaches. The true promise of this modality, however, only materializes when it is woven into the fabric of precision medicine. By leveraging whole-exome sequenc-ing, artificial intelligence-driven neoantigen prediction, single-cell transcriptomics, and real-time liquid biopsy monitoring, clinicians can now select targets, engineer receptors, and triage patients with a granularity that was unimaginable a decade ago. This narrative review synthe-sizes peer-reviewed literature from 2015 to 2025, drawing from PubMed, Elsevier, Wiley, and Springer databases, to examine how the fusion of TCR-T therapy and precision oncology is re-shaping target identification, manufacturing workflows, and clinical outcomes. We highlight landmark trials—including the SPEARHEAD-1 study leading to FDA accelerated approval of afamitresgene autoleucel for synovial sarcoma—and discuss how CRISPR editing, allogeneic platforms, and rational combination regimens are addressing historical barriers such as tumor heterogeneity, T cell exhaustion, and prohibitive manufacturing costs. Our analysis suggests that the next chapter of adoptive cell therapy will not be defined by a single breakthrough, but by the creation of an integrated precision ecosystem that aligns tumor biology, immune engineer-ing, and patient-specific biomarkers from diagnosis through post-treatment surveillance.